Sinopharm Group Co. Ltd. (SHTDY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sinopharm Group Co. Ltd. (SHTDY) with AI Score 42/100 (Weak). Sinopharm Group Co. Ltd. is a leading pharmaceutical and healthcare product distributor in China. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Sinopharm Group Co. Ltd. (SHTDY) Healthcare & Pipeline Overview
Sinopharm Group Co. Ltd., a major player in China's healthcare sector, distributes pharmaceuticals, medical devices, and healthcare products. With a vast retail pharmacy network and strategic partnerships like the one with I-Mab, Sinopharm aims to enhance its commercial capabilities and market reach across the People's Republic of China.
Investment Thesis
Sinopharm Group Co. Ltd. presents a compelling investment case based on its established market position in China's growing healthcare sector. With a P/E ratio of 8.52 and a dividend yield of 3.50%, the company offers potential value and income. Growth catalysts include the expansion of its retail pharmacy network and strategic partnerships to enhance commercial capabilities. However, investors may want to evaluate the relatively low profit margin of 1.2% and the potential risks associated with operating in a highly regulated industry. The company's beta of 0.62 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $8.40 billion, reflecting its significant presence in the healthcare distribution market.
- P/E ratio of 8.52, indicating a potentially undervalued stock compared to its earnings.
- Dividend yield of 3.50%, offering a steady income stream for investors.
- Gross margin of 7.5%, highlighting the efficiency of its operations in a competitive market.
- Operates 10,259 retail pharmacies as of December 31, 2021, providing a strong retail presence.
Competitors & Peers
Strengths
- Extensive distribution network in China.
- Large retail pharmacy presence.
- Strategic partnerships with key industry players.
- Diversified business segments.
Weaknesses
- Relatively low profit margin.
- Dependence on the Chinese market.
- Exposure to regulatory changes in the healthcare industry.
- Limited international presence.
Catalysts
- Ongoing: Expansion of retail pharmacy network to increase market reach.
- Ongoing: Strategic partnerships to enhance commercial capabilities and product offerings.
- Upcoming: Potential regulatory approvals for new pharmaceutical products.
- Ongoing: Growth in the Chinese healthcare market driven by an aging population.
- Ongoing: Increased demand for medical devices and healthcare services in China.
Risks
- Potential: Regulatory changes in the Chinese healthcare industry.
- Potential: Intense competition from domestic and international players.
- Ongoing: Currency risk associated with investing in an ADR.
- Potential: Limited financial disclosure due to OTC listing.
- Potential: Economic slowdown in China affecting healthcare spending.
Growth Opportunities
- Expansion of Retail Pharmacy Network: Sinopharm can further expand its retail pharmacy network, particularly in underserved regions of China. The increasing demand for prescription drugs and over-the-counter medications presents a significant growth opportunity. By increasing its retail footprint, Sinopharm can capture a larger share of the retail pharmaceutical market. The company had 10,259 retail pharmacies as of December 31, 2021, and continuing to grow this number will drive revenue growth.
- Strategic Partnerships and Alliances: Sinopharm's strategic partnership with I-Mab demonstrates its commitment to enhancing commercial capabilities and commercializing innovative products. Forming additional partnerships with pharmaceutical manufacturers and technology companies can drive innovation and expand its product offerings. These partnerships can also provide access to new markets and technologies, further strengthening Sinopharm's competitive position.
- Growth in Medical Device Distribution: The increasing demand for advanced medical devices in China presents a significant growth opportunity for Sinopharm. By expanding its distribution network and product portfolio in the medical device segment, Sinopharm can capitalize on this growing market. This includes distributing high-end diagnostic equipment, surgical instruments, and other medical technologies. Investing in logistics and supply chain infrastructure will be crucial to support this growth.
- Expansion into Specialty Pharmaceuticals: Sinopharm can expand its focus on specialty pharmaceuticals, which often command higher margins and address unmet medical needs. This includes developing or acquiring specialty drugs for chronic diseases, oncology, and other therapeutic areas. By focusing on specialty pharmaceuticals, Sinopharm can differentiate itself from competitors and drive revenue growth. This strategy requires investment in research and development or strategic acquisitions.
- Leveraging E-commerce and Digital Health: The increasing adoption of e-commerce and digital health technologies in China presents a significant opportunity for Sinopharm. By developing online platforms and digital health services, Sinopharm can reach a wider customer base and enhance customer engagement. This includes offering online prescription refills, virtual consultations, and other digital health solutions. Investing in digital infrastructure and cybersecurity will be crucial to support this growth.
Opportunities
- Expansion into underserved regions of China.
- Growth in the medical device market.
- Development of e-commerce and digital health platforms.
- Increased focus on specialty pharmaceuticals.
Threats
- Intense competition from domestic and international players.
- Price pressures from government regulations.
- Potential disruptions from new technologies.
- Economic slowdown in China.
Competitive Advantages
- Extensive distribution network across China.
- Large retail pharmacy network.
- Strategic partnerships with pharmaceutical manufacturers.
- Established brand reputation in the Chinese healthcare market.
About SHTDY
Founded in 2003 and headquartered in Shanghai, Sinopharm Group Co. Ltd. has grown into a comprehensive healthcare conglomerate. The company operates through four primary segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment is responsible for distributing pharmaceutical products to a wide network of hospitals, distributors, retail drug stores, and clinics, offering value-added services to both domestic and international manufacturers. The Medical Devices segment focuses on the distribution of various medical devices. The Retail Pharmacy segment manages an extensive network of over 10,259 retail pharmacies as of December 31, 2021, providing direct access to consumers. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Sinopharm also offers a range of services including property rental and management, distribution of medical instruments and traditional Chinese medicines, IT development, and consulting services. The company's strategic partnership with I-Mab aims to bolster its commercial capabilities and accelerate the commercialization of innovative products. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
What They Do
- Wholesale and retail of pharmaceutical products.
- Distribution of medical devices.
- Operation and franchising of retail drug stores.
- Production and sale of pharmaceutical products.
- Distribution of chemical reagents and laboratory supplies.
- Property rental and management.
- Distribution of medical instruments, Chinese herbal medicines, antibiotics, and biological products.
Business Model
- Distribution of pharmaceuticals and medical devices to hospitals, distributors, and retail stores.
- Operation of a retail pharmacy network.
- Production and sale of pharmaceutical products and related supplies.
- Providing logistics and value-added services to manufacturers.
Industry Context
Sinopharm Group Co. Ltd. operates within the rapidly expanding Chinese healthcare market, driven by an aging population and increasing healthcare spending. The market is characterized by intense competition among domestic and international players. Sinopharm's extensive distribution network and retail pharmacy presence provide a competitive advantage. The company's focus on pharmaceutical distribution and medical devices aligns with the growing demand for these products and services in China. Competitors include GIFOF, MSMKF, SHPMF, SHPMY, and SSMXF.
Key Customers
- Hospitals and clinics.
- Other pharmaceutical distributors.
- Retail drug stores.
- Pharmaceutical and healthcare product manufacturers.
Financials
Chart & Info
Sinopharm Group Co. Ltd. (SHTDY) stock price: Price data unavailable
Latest News
-
Sinopharm Explores Noninvasive Glucose Monitoring To Deepen China Diabetes Role
Yahoo! Finance: SHTDY News · Mar 21, 2026
-
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
Yahoo! Finance: SHTDY News · Mar 19, 2026
-
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
accessnewswire.com · Mar 19, 2026
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHTDY.
Price Targets
Wall Street price target analysis for SHTDY.
MoonshotScore
What does this score mean?
The MoonshotScore rates SHTDY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Sinopharm Explores Noninvasive Glucose Monitoring To Deepen China Diabetes Role
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
Stocks That Hit 52-Week Highs On Tuesday
Leadership: Wanyong Lian
CEO
Wanyong Lian serves as the CEO of Sinopharm Group Co. Ltd., leading a workforce of over 108,000 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on distribution and retail operations. He has held various leadership positions within Sinopharm, contributing to the company's growth and expansion. His expertise spans strategic planning, operational management, and business development.
Track Record: Under Wanyong Lian's leadership, Sinopharm has strengthened its market position in China's healthcare sector. Key achievements include expanding the retail pharmacy network and forging strategic partnerships to enhance commercial capabilities. He has also overseen the company's efforts to adapt to changing market dynamics and regulatory requirements. His tenure has been marked by a focus on innovation and efficiency.
Sinopharm Group Co. Ltd. ADR Information Unsponsored
An American Depositary Receipt (ADR) like SHTDY represents shares of a foreign company (Sinopharm Group Co. Ltd.) held by a U.S. depositary bank. It allows U.S. investors to trade shares of a Chinese company on U.S. exchanges. SHTDY provides a convenient way to invest in Sinopharm without directly dealing with foreign markets.
- Home Market Ticker: Shanghai Stock Exchange, China
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SHTD
SHTDY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sinopharm Group Co. Ltd. has chosen not to meet the requirements for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is also known as the Pink Sheets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in SHTDY.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- OTC Other tier designation indicates a higher level of risk compared to stocks listed on major exchanges.
- Potential for fraud or manipulation due to less regulatory oversight.
- Dependence on the Chinese market and regulatory environment.
- Verify the company's registration and legal status.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and track record.
- Understand the company's business model and competitive landscape.
- Evaluate the risks associated with investing in a Chinese company.
- Monitor news and developments related to the company and its industry.
- Consult with a financial advisor before investing.
- Subsidiary of Sinopharm Industrial Investment Co., Ltd.
- Established presence in the Chinese healthcare market.
- Strategic partnership with I-Mab.
- Significant number of employees (108217).
Common Questions About SHTDY
What does Sinopharm Group Co. Ltd. do?
Sinopharm Group Co. Ltd. is a leading distributor of pharmaceuticals, medical devices, and healthcare products in China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. It distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. Additionally, Sinopharm operates a large network of retail pharmacies and produces pharmaceutical products, chemical reagents, and laboratory supplies. The company also provides logistics and value-added services to manufacturers.
What do analysts say about SHTDY stock?
Analyst coverage of SHTDY is limited due to its OTC listing and ADR Level I status. However, key valuation metrics such as its P/E ratio of 8.52 and dividend yield of 3.50% suggest potential value. Growth considerations include the company's expansion in the Chinese healthcare market and strategic partnerships. Investors should conduct their own due diligence and consider the risks associated with investing in an OTC stock.
What are the main risks for SHTDY?
The main risks for SHTDY include regulatory changes in the Chinese healthcare industry, intense competition from domestic and international players, and currency risk associated with investing in an ADR. Additionally, the OTC listing and limited financial disclosure increase the risk of investing in SHTDY. Economic slowdown in China could also affect healthcare spending and the company's performance. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for SHTDY?
Sinopharm Group Co. Ltd. (SHTDY) currently holds an AI score of 42/100, indicating low score. Key strength: Extensive distribution network in China.. Primary risk to monitor: Potential: Regulatory changes in the Chinese healthcare industry.. This is not financial advice.
How frequently does SHTDY data refresh on this page?
SHTDY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SHTDY's recent stock price performance?
Recent price movement in Sinopharm Group Co. Ltd. (SHTDY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Extensive distribution network in China.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SHTDY overvalued or undervalued right now?
Determining whether Sinopharm Group Co. Ltd. (SHTDY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SHTDY?
Before investing in Sinopharm Group Co. Ltd. (SHTDY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Disclosure status is unknown, which increases risk.